Biosimilars in inflammatory bowel disease: ready for prime time?

Area of Science:

• Gastroenterology
• Pharmacology
• Regulatory Science

Background:

• Biosimilars, particularly infliximab biosimilars, are increasingly relevant in managing inflammatory bowel disease (IBD).
• The high cost of biologic therapies significantly impacts IBD treatment accessibility and resource allocation in healthcare.
• Regulatory pathways for biosimilars differ from reference biologics, emphasizing in-vitro studies and fewer clinical trials.

Purpose of the Study:

• To review current literature on biosimilars in IBD.
• To focus on the controversial regulatory aspects, particularly the extrapolation of indications.

Main Methods:

• Literature review of recent studies on biosimilars in IBD.
• Analysis of regulatory guidelines and scientific position statements regarding biosimilar evaluation and extrapolation.

Main Results:

• Biosimilar approval, like CT-P13 (infliximab), is a significant development in IBD and rheumatology.
• Regulatory agencies accept 'high similarity' based on extensive in-vitro data, with limited clinical trials.
• Controversy exists regarding the extrapolation of indications to IBD without direct clinical evidence, with differing stances between agencies like EMA and Health Canada.

Conclusions:

• Biosimilars are established in IBD management.
• Further clinical data are needed to resolve extrapolation controversies.
• Market dynamics will determine if biosimilars enhance competition and reduce biologic drug costs for IBD patients.